Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reports that spironolactone has shown effectiveness in improving hair density and reducing shedding in female pattern hair loss, particularly for women with hyperandrogenism, though benefits often diminish after stopping treatment.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This study found that GnRH-a treatment or orchiectomy, which required significantly lower doses of oral estradiol valerate, were more effective than anti-androgens like spironolactone and finasteride in achieving target hormone levels in transgender females in India.

This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.

This study concluded that Buserelin can effectively inhibit gonadal activity in children with central precocious puberty over 18 months, potentially improving final height predictions with prolonged treatment.

This study found that spironolactone directly inhibits 5 alpha-reductase activity in hirsute women, resulting in decreased conversion of testosterone to dihydrotestosterone, which may contribute to its therapeutic effects.

This study reports the development of novel 4-amido-Δ4,6-steroids as potential inhibitors of 5α-reductase, showing promising in vitro results for conditions like acne and benign prostatic cancer.

This study found that a 1% Sandalore® solution reduced hair shedding and improved hair volume and anagen phase duration in women with telogen effluvium over 24 weeks, compared to placebo.

This study found that in non-obese women with moderate body hair growth, DHEA-S and prolactin levels were higher, and SBP was lower compared to controls, which may inform treatment decisions.

This source reports that clascoterone cream, a topical androgen receptor inhibitor, has shown effectiveness in treating facial acne vulgaris in patients 12 and older, with clinical trials indicating a favorable safety profile compared to systemic treatments, and potential for broader dermatological applications.

This review discusses the potential and varied uses of spironolactone in dermatological conditions such as acne, hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia, emphasizing dosage, treatment recommendations, and adverse effects for practical clinical use.

This article reviews endocrine therapies for androgen excess disorders, emphasizing spironolactone, estrogen, and dexamethasone as effective treatments; it reports no new clinical results.

This trial explores whether spironolactone is more effective than cyclines for treating moderate acne in adult women, providing a potential alternative amidst concerns over antibiotic resistance.

This report shares the authors' experience using spironolactone for treating acne in a PCOS clinic, but provides no new clinical results.

This study found that liposterolic extracts of Serenoa repens enhanced hair regeneration and repair in DHT-induced hair loss mouse models, suggesting potential effects comparable to finasteride.

This study concluded that spironolactone may be an effective therapy for a subgroup of hirsute patients, as it reduced plasma testosterone and improved certain hair growth measures.

This review concludes that the global literature supports the efficacy and safety of lipidosterolic extract of Serenoa repens in treating lower urinary tract symptoms, comparable to alpha-blockers and 5α-reductase inhibitors.

This study found that a low estrogen-containing oral contraceptive normalized hormone levels and improved symptoms in women with polycystic ovary disease, with minimal side effects reported.

This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.

This study found that medroxyprogesterone acetate treatment in women with PCOS reduced hyperandrogenism-related hormonal levels and improved skin conditions without affecting lipid or carbohydrate metabolism.

This study found that oral estradiol was generally effective in achieving target 17-β estradiol levels in transgender women, but often failed to suppress testosterone adequately, with variability in individual responses.

This study reported that both drospirenone and chlormadinone acetate oral contraceptives had similar beneficial effects on clinical, metabolic, and hormonal parameters in women with polycystic ovary syndrome over six months.

This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.

This study suggests that nanostructured lipid carriers loaded with spironolactone might improve localized delivery to hair follicles for treating androgenic alopecia, potentially minimizing systemic side effects.

This study observed that spironolactone improved hidradenitis suppurativa in over 80% of female patients at 3 and 6 months, with no significant differences in response due to menstrual flares or polycystic ovarian syndrome, but mild adverse events were reported.

This article reviews various updates in dermatology, including drug safety alerts and treatment options, and reports no new clinical results.

This study found that Diane®, a combination of cyproterone acetate and ethinyl estradiol, is an effective contraceptive and treatment for acne and seborrhea, but less effective for pronounced hair growth.

This study found that the combination of ethinylestradiol and desogestrel significantly decreased hair growth and hormone levels in hirsute women, suggesting a relationship between hormone changes and treatment effectiveness.

This review discusses the pharmacological properties of progestins used in contraception and hormone replacement therapy, focusing on drospirenone's unique effects, but reports no new experimental findings.